Firm- and Drug-Specific Patterns of Generic Drug Payments by US Medicaid Programs: 1991–2008

Christina Kelton (), Lenisa Chang (), Jeff Guo (), Yan Yu (), Edmund Berry (), Boyang Bian () and Pamela Heaton ()

Applied Health Economics and Health Policy, 2014, vol. 12, issue 2, 165-177

Abstract: State Medicaid programmes generally have been able to obtain relief from high drug prices following patent expirations for many branded-drug medications by adjusting reimbursement following the expanded competition in the pharmaceutical market. Copyright Springer International Publishing Switzerland 2014

Date: 2014
References: View references in EconPapers View complete reference list from CitEc
Citations: View citations in EconPapers (2)

Downloads: (external link)
http://hdl.handle.net/10.1007/s40258-014-0083-z (text/html)
Access to full text is restricted to subscribers.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:aphecp:v:12:y:2014:i:2:p:165-177

Ordering information: This journal article can be ordered from
http://www.springer.com/economics/journal/40258

DOI: 10.1007/s40258-014-0083-z

Access Statistics for this article

Applied Health Economics and Health Policy is currently edited by Timothy Wrightson

More articles in Applied Health Economics and Health Policy from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().